ACAD
Price
$26.86
Change
+$0.40 (+1.51%)
Updated
Jan 14 closing price
Capitalization
4.54B
46 days until earnings call
Intraday BUY SELL Signals
RXRX
Price
$4.85
Change
+$0.16 (+3.41%)
Updated
Jan 14 closing price
Capitalization
2.52B
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ACAD vs RXRX

Header iconACAD vs RXRX Comparison
Open Charts ACAD vs RXRXBanner chart's image
ACADIA Pharmaceuticals
Price$26.86
Change+$0.40 (+1.51%)
Volume$951.83K
Capitalization4.54B
Recursion Pharmaceuticals
Price$4.85
Change+$0.16 (+3.41%)
Volume$16.95M
Capitalization2.52B
ACAD vs RXRX Comparison Chart in %
View a ticker or compare two or three
VS
ACAD vs. RXRX commentary
Jan 15, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and RXRX is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jan 15, 2026
Stock price -- (ACAD: $26.86 vs. RXRX: $4.85)
Brand notoriety: ACAD and RXRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 67% vs. RXRX: 73%
Market capitalization -- ACAD: $4.54B vs. RXRX: $2.52B
ACAD [@Biotechnology] is valued at $4.54B. RXRX’s [@Biotechnology] market capitalization is $2.52B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.05B to $0. The average market capitalization across the [@Biotechnology] industry is $2.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 1 FA rating(s) are green whileRXRX’s FA Score has 1 green FA rating(s).

  • ACAD’s FA Score: 1 green, 4 red.
  • RXRX’s FA Score: 1 green, 4 red.
According to our system of comparison, ACAD is a better buy in the long-term than RXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 4 TA indicator(s) are bullish while RXRX’s TA Score has 5 bullish TA indicator(s).

  • ACAD’s TA Score: 4 bullish, 4 bearish.
  • RXRX’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, RXRX is a better buy in the short-term than ACAD.

Price Growth

ACAD (@Biotechnology) experienced а -2.04% price change this week, while RXRX (@Biotechnology) price change was -0.21% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.31%. For the same industry, the average monthly price growth was +3.20%, and the average quarterly price growth was +43.69%.

Reported Earning Dates

ACAD is expected to report earnings on Mar 02, 2026.

RXRX is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+0.31% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($4.54B) has a higher market cap than RXRX($2.52B). RXRX YTD gains are higher at: 18.582 vs. ACAD (0.562). ACAD has higher annual earnings (EBITDA): 108M vs. RXRX (-636.09M). ACAD has more cash in the bank: 847M vs. RXRX (660M). ACAD has less debt than RXRX: ACAD (54.8M) vs RXRX (82.4M). ACAD has higher revenues than RXRX: ACAD (1.05B) vs RXRX (43.4M).
ACADRXRXACAD / RXRX
Capitalization4.54B2.52B180%
EBITDA108M-636.09M-17%
Gain YTD0.56218.5823%
P/E Ratio17.32N/A-
Revenue1.05B43.4M2,412%
Total Cash847M660M128%
Total Debt54.8M82.4M67%
FUNDAMENTALS RATINGS
ACAD: Fundamental Ratings
ACAD
OUTLOOK RATING
1..100
70
VALUATION
overvalued / fair valued / undervalued
1..100
69
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
26
PRICE GROWTH RATING
1..100
43
P/E GROWTH RATING
1..100
82
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACADRXRX
RSI
ODDS (%)
Bearish Trend 3 days ago
67%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 1 day ago
89%
Momentum
ODDS (%)
Bearish Trend 3 days ago
61%
Bullish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 3 days ago
75%
Bullish Trend 1 day ago
79%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 1 day ago
87%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
73%
Bullish Trend 1 day ago
83%
Advances
ODDS (%)
Bullish Trend 9 days ago
76%
Bullish Trend 9 days ago
84%
Declines
ODDS (%)
Bearish Trend 3 days ago
70%
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
80%
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
75%
Bearish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ACAD
Daily Signal:
Gain/Loss:
RXRX
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DEVCX44.940.21
+0.47%
Nomura Small Cap Value C
VWINX25.800.09
+0.35%
Vanguard Wellesley® Income Inv
IGMIX11.06-0.03
-0.27%
Voya Global Insights Portfolio I
MLNIX27.63-0.21
-0.75%
Morgan Stanley Instl Glbl Concntr I
TPYCX8.72-0.11
-1.25%
Touchstone Sands Capital Intl Gr Eq C

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with STTK. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then STTK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
+1.51%
STTK - ACAD
39%
Loosely correlated
+4.88%
RXRX - ACAD
38%
Loosely correlated
+3.41%
AURA - ACAD
38%
Loosely correlated
+3.95%
VCYT - ACAD
36%
Loosely correlated
-1.39%
MIRM - ACAD
36%
Loosely correlated
+0.23%
More

RXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, RXRX has been closely correlated with CRSP. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if RXRX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RXRX
1D Price
Change %
RXRX100%
+3.41%
CRSP - RXRX
68%
Closely correlated
+1.26%
ABSI - RXRX
66%
Closely correlated
+1.21%
BEAM - RXRX
62%
Loosely correlated
+2.49%
ABCL - RXRX
58%
Loosely correlated
+0.47%
PRME - RXRX
54%
Loosely correlated
+3.61%
More